Welcome to our dedicated page for Bioadaptives news (Ticker: BDPT), a resource for investors and traders seeking the latest updates and insights on Bioadaptives stock.
BioAdaptives, Inc. develops and markets nutraceutical and wellness products for cognitive performance, brain recovery, pet vitality and weight management. Company news centers on the MyndSystem platform, including MyndMed for daytime cognitive support and MyndRenew for nighttime recovery support, as well as NeuroRush, PawPa Regen dog chews and Zeranovia.
Recurring updates cover product launches, direct-to-consumer availability, formulation positioning, pilot and dosage testing, athlete-safety testing for MyndMed, and expansion of pet-wellness and nootropic product lines.
BioAdaptives, Inc. (OTCMkts: BDPT) announces a collaboration with Professor Lorrin Koran from Stanford Medical Center for research on PluriPain®, aimed at alleviating chronic pain linked to Gadolinium Deposition Disease. This rare disorder surfaces in patients exposed to gadolinium from MRI contrast agents, resulting in prolonged pain through inflammatory cytokine production. BioAdaptives will supply PluriPain® for this research, furthering its commitment to addressing inflammatory pain issues.
BioAdaptives (OTCMkts: BDPT) announced the launch of its Ambassador Program for the Livestock Impact Division, promoting products like Equine All-in-One™ and Canine Regen®. The program aims to enhance affiliate marketing through social media and discounts, targeting industry participants. Notably, Equine All-in-One™ is a plant-based supplement reported to improve horse health and performance, while Canine Regen® supports dog health and regeneration. The initiative will be led by COO Charles Townsend, with plans for national and potential international outreach.
BioAdaptives, Inc. (OTCMkts: BDPT) has entered a Licensing and Co-Marketing Agreement with The Fedr8tion Ltd., which has 11 million affiliate members. This partnership allows BioAdaptives to offer special membership pricing on its nutraceuticals through Fedr8tion’s platform, enhancing its reach to a new demographic within the e-gaming community. The collaboration aims to introduce BioAdaptives' natural supplement products to a younger audience engaged in e-sports, leveraging Fedr8tion's established member base and marketing capabilities.
BioAdaptives, Inc. (OTCMkts: BDPT) announces key executive appointments: Charles Townsend is appointed Chief Operating Officer and director, Robert W. Ellis remains President and becomes a director, and Ronald Lambrecht is reappointed Chief Financial Officer. Townsend brings over 30 years of experience from various sectors, including operations and enterprise marketing, enhancing the leadership team's strength. The company focuses on natural health products for humans and animals, emphasizing wellness and innovative formulations.
BioAdaptives, Inc. (OTCMkts: BDPT) has launched a new social media advertising campaign aimed at promoting its pain relief and immune-boosting products. Partnering with J Ramsdell Consulting and The Dropup Agency, the company will utilize targeted marketing through Click Funnels and social platforms like Facebook, Instagram, and YouTube. CEO Edward Jacobs highlighted years of research leading to advanced formulations, anticipating significant revenue growth from this initiative. The company manufactures natural health products, emphasizing pain relief and immune defense, with a commitment to holistic wellness.